Eptifibatide Ctruz
Glycoprotein IIb/IIIa receptor antagonist — antiplatelet agent for acute coronary syndrome
Quick Facts About Eptifibatide Ctruz
Key Takeaways About Eptifibatide Ctruz
- Hospital-only medication: Eptifibatide Ctruz is administered intravenously only in hospital settings by healthcare professionals experienced in managing acute coronary syndromes
- Prevents blood clots: Works by reversibly blocking the GP IIb/IIIa receptor on platelets, preventing fibrinogen binding and platelet aggregation that leads to clot formation
- Bleeding is the main risk: The most significant side effect is bleeding, ranging from minor bruising to serious hemorrhage; close monitoring of platelet counts and coagulation parameters is essential
- Used with aspirin and heparin: Typically administered as part of a combination antiplatelet and anticoagulant regimen for acute coronary syndrome management
- Dose adjustment in renal impairment: Patients with moderate kidney impairment require reduced infusion rates; the drug is contraindicated in patients requiring dialysis
What Is Eptifibatide Ctruz and What Is It Used For?
Eptifibatide Ctruz is a glycoprotein IIb/IIIa receptor antagonist (antiplatelet agent) used to prevent blood clot formation in patients with acute coronary syndrome (ACS), including unstable angina and non-ST-elevation myocardial infarction (NSTEMI). It is also used during percutaneous coronary intervention (PCI) procedures such as coronary stenting.
Eptifibatide is a synthetic cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of glycoprotein (GP) IIb/IIIa receptor antagonists, which are among the most potent antiplatelet agents available in clinical practice. The GP IIb/IIIa receptor is the most abundant receptor on the platelet surface and plays a central role in the final common pathway of platelet aggregation.
When a coronary artery becomes narrowed or blocked due to atherosclerotic plaque rupture, platelets are activated and aggregate at the site of injury, forming a thrombus (blood clot) that can further restrict or completely block blood flow to the heart muscle. This process underlies acute coronary syndromes, which include unstable angina and myocardial infarction (heart attack). Eptifibatide works by competitively and reversibly binding to the GP IIb/IIIa receptor, thereby preventing fibrinogen and von Willebrand factor from cross-linking activated platelets. This inhibition of the final common pathway of platelet aggregation significantly reduces the risk of thrombus formation.
Eptifibatide Ctruz is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-ST-elevation myocardial infarction (NSTEMI), with the last episode of chest pain occurring within 24 hours and with electrocardiographic changes and/or elevated cardiac biomarkers. It is intended for use together with acetylsalicylic acid (aspirin) and unfractionated heparin. Additionally, eptifibatide is indicated for the reduction of thrombotic complications during percutaneous coronary intervention (PCI), including patients undergoing intracoronary stent placement.
Unlike oral antiplatelet agents such as aspirin or clopidogrel, which inhibit specific activation pathways, eptifibatide blocks the final common pathway of platelet aggregation at the GP IIb/IIIa receptor. This provides more complete inhibition of platelet aggregation. Other GP IIb/IIIa inhibitors include abciximab (a monoclonal antibody fragment) and tirofiban (a non-peptide antagonist). Eptifibatide has a shorter duration of action compared to abciximab, with platelet function returning to near-normal within 4 hours of stopping the infusion, which can be advantageous in patients who may require urgent surgery.
What Should You Know Before Receiving Eptifibatide Ctruz?
Eptifibatide Ctruz carries a significant risk of bleeding and is contraindicated in patients with active bleeding, recent stroke, major surgery within 6 weeks, or severe kidney disease requiring dialysis. A thorough assessment of bleeding risk factors is essential before starting treatment.
Contraindications
Eptifibatide Ctruz must not be used in the following situations, as the risk of life-threatening bleeding may outweigh the potential benefits:
- Active internal bleeding or history of clinically significant gastrointestinal or genitourinary bleeding within the previous 30 days
- History of hemorrhagic stroke within the past 30 days or any history of hemorrhagic stroke with residual neurological deficit
- History of ischemic stroke within the previous 30 days
- Major surgery or severe trauma within the previous 6 weeks
- Intracranial disease including known intracranial neoplasm, arteriovenous malformation, or aneurysm
- Severe uncontrolled hypertension (systolic blood pressure >200 mmHg or diastolic blood pressure >110 mmHg despite treatment)
- Thrombocytopenia with platelet count below 100,000/mm3
- Severe hepatic impairment with clinically relevant coagulopathy
- Severe renal impairment (creatinine clearance <30 ml/min) or patients requiring dialysis
- Concomitant or planned use of another GP IIb/IIIa inhibitor
- Hypersensitivity to eptifibatide or any of the excipients
Warnings and Precautions
The primary risk associated with eptifibatide therapy is bleeding. Healthcare professionals must carefully weigh the benefits of treatment against the risk of hemorrhage for each individual patient. Special caution is required in the following situations:
- Elderly patients (over 65 years): Higher risk of bleeding complications. Dose adjustments are not required based on age alone, but careful monitoring is essential.
- Low body weight: Patients weighing less than 60 kg may have an increased risk of bleeding and should be monitored closely.
- Moderate renal impairment (creatinine clearance 30-50 ml/min): The infusion rate must be reduced, as eptifibatide is primarily cleared by renal excretion. The bolus dose remains unchanged.
- Concomitant use of other antithrombotic agents: The risk of bleeding is significantly increased when eptifibatide is used with thrombolytic agents, oral anticoagulants, or dextran solutions.
- Vascular puncture sites: Careful attention to potential bleeding sites is required, particularly at arterial access sites for cardiac catheterization.
During eptifibatide therapy, platelet count, hemoglobin, hematocrit, and activated clotting time (ACT) or activated partial thromboplastin time (aPTT) should be monitored regularly. If thrombocytopenia develops (platelet count falling below 100,000/mm3), eptifibatide and heparin should be discontinued immediately, and the condition should be appropriately monitored and treated.
Eptifibatide Ctruz inhibits platelet aggregation and increases the risk of bleeding. Serious and sometimes fatal bleeding events, including intracranial hemorrhage and retroperitoneal bleeding, have been reported. If serious bleeding occurs that cannot be controlled with pressure, the infusion must be stopped immediately. There is no specific antidote for eptifibatide, but platelet function typically returns to near-normal within 4 hours of discontinuation.
Pregnancy and Breastfeeding
There are no adequate and well-controlled studies of eptifibatide in pregnant women. Animal reproduction studies have not demonstrated direct harmful effects on pregnancy, embryonal or fetal development, parturition, or postnatal development. However, eptifibatide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Given that acute coronary syndromes in pregnancy are medical emergencies, the decision to use eptifibatide should be made on a case-by-case basis by the treating cardiologist and obstetrician.
It is not known whether eptifibatide is excreted in human breast milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the drug to the mother. Given the short duration of treatment (typically 24-96 hours) and the rapid clearance of the drug, breastfeeding may be resumed after treatment completion following medical advice.
How Does Eptifibatide Ctruz Interact with Other Drugs?
Eptifibatide Ctruz interacts primarily with other agents that affect hemostasis, including anticoagulants, thrombolytics, and antiplatelet drugs. While it is intentionally used with aspirin and heparin in clinical practice, concomitant use with other antithrombotic agents significantly increases bleeding risk.
Since eptifibatide inhibits platelet aggregation, any concomitant use of drugs that also affect hemostasis can increase the risk of bleeding. The interactions described below are based on clinical experience, pharmacological principles, and post-marketing surveillance data. Healthcare professionals managing patients on eptifibatide should maintain a comprehensive medication review.
Major Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Thrombolytics (alteplase, tenecteplase, streptokinase) | Markedly increased bleeding risk due to dual inhibition of coagulation cascade and platelet aggregation | Avoid combination unless benefits clearly outweigh risks; increased risk of intracranial hemorrhage |
| Other GP IIb/IIIa inhibitors (abciximab, tirofiban) | Additive and potentially synergistic inhibition of platelet aggregation | Contraindicated — concurrent use of multiple GP IIb/IIIa inhibitors must be avoided |
| Oral anticoagulants (warfarin, rivaroxaban, apixaban, dabigatran) | Increased bleeding risk through combined inhibition of coagulation and platelet function | Avoid combination; if necessary, use with extreme caution and close monitoring of INR/coagulation parameters |
| Dextran solutions | Dextran impairs platelet function and may increase bleeding when combined with eptifibatide | Avoid concomitant use with dextran solutions |
Intended Concurrent Therapy
| Drug / Class | Interaction | Clinical Notes |
|---|---|---|
| Aspirin (acetylsalicylic acid) | Additive antiplatelet effect; aspirin inhibits COX-1 while eptifibatide blocks GP IIb/IIIa | Standard combination; aspirin 150-325 mg recommended unless contraindicated |
| Unfractionated heparin (UFH) | Complementary anticoagulant effect; heparin inhibits thrombin while eptifibatide inhibits platelet aggregation | Standard combination; target aPTT 50-70 seconds; reduce heparin dose during PCI per protocol |
| Clopidogrel / Ticagrelor | Additional antiplatelet effect through P2Y12 receptor inhibition combined with GP IIb/IIIa blockade | May be used per interventional cardiology protocols; increased bleeding risk requires careful monitoring |
Minor Interactions
Eptifibatide has no known clinically significant interactions with drugs metabolized by cytochrome P450 enzymes, as it is primarily eliminated through renal excretion and plasma deamidation rather than hepatic metabolism. Common cardiovascular medications including beta-blockers, ACE inhibitors, calcium channel blockers, and statins can be safely continued during eptifibatide treatment without dose modifications. Non-steroidal anti-inflammatory drugs (NSAIDs) may modestly increase bleeding risk due to their antiplatelet effects and should be used with caution.
What Is the Correct Dosage of Eptifibatide Ctruz?
Eptifibatide Ctruz is administered as an intravenous bolus injection followed by a continuous infusion. The standard dose for acute coronary syndrome is a 180 mcg/kg bolus followed by 2.0 mcg/kg/min infusion for up to 72 hours. For PCI, a double bolus (180 mcg/kg each, 10 minutes apart) is given with 2.0 mcg/kg/min infusion for 20-24 hours post-procedure.
Eptifibatide Ctruz is intended for use by physicians experienced in the management of acute coronary syndromes. It is administered intravenously only and must not be given by any other route. The dosing regimen depends on the clinical indication and the patient's renal function. Eptifibatide Ctruz is available as a solution for infusion at a concentration of 0.75 mg/ml.
Adults with Normal Renal Function
| Indication | Bolus Dose | Infusion Rate | Duration |
|---|---|---|---|
| Unstable angina / NSTEMI | 180 mcg/kg IV bolus (max 22.6 mg) | 2.0 mcg/kg/min continuous infusion | Up to 72 hours (up to 96 hours if PCI performed during treatment) |
| Percutaneous Coronary Intervention (PCI) | 180 mcg/kg IV bolus, repeated 10 min later (double bolus) | 2.0 mcg/kg/min continuous infusion | 20-24 hours after PCI procedure |
Patients with Renal Impairment
Moderate Renal Impairment (Creatinine Clearance 30-50 ml/min)
The bolus dose remains unchanged at 180 mcg/kg. The infusion rate must be reduced to 1.0 mcg/kg/min. During PCI, the second bolus of 180 mcg/kg should also be administered 10 minutes after the first bolus.
Severe Renal Impairment (Creatinine Clearance <30 ml/min) or Dialysis
Eptifibatide Ctruz is contraindicated in patients with severe renal impairment or those requiring hemodialysis. The drug is primarily eliminated by renal excretion, and drug accumulation in these patients significantly increases bleeding risk.
Children and Adolescents
The safety and efficacy of eptifibatide in children and adolescents under 18 years of age have not been established. No data are available. Acute coronary syndromes are exceedingly rare in the pediatric population, and eptifibatide is not recommended for use in patients under 18 years of age.
Elderly Patients
No dosage adjustment is required based on age alone. However, elderly patients are at increased risk of bleeding complications due to age-related changes in vascular integrity, increased likelihood of concomitant medications that affect hemostasis, and potentially reduced renal function. Renal function should be assessed before starting treatment, and the dose should be adjusted based on creatinine clearance rather than age. Careful monitoring of bleeding parameters is particularly important in elderly patients.
Missed Dose
Since eptifibatide is administered as a continuous intravenous infusion in a hospital setting by healthcare professionals, missed doses are managed by the clinical team. If an infusion is accidentally interrupted, it should be restarted as soon as possible following the prescribed protocol. The decision whether to administer an additional bolus depends on the duration of interruption and the clinical situation, as determined by the treating physician.
Overdose
There is limited experience with overdose of eptifibatide in clinical trials. Symptoms of overdose would be expected to manifest primarily as bleeding complications. There is no specific antidote for eptifibatide. In the event of overdose, the infusion should be stopped immediately. Eptifibatide has a short plasma half-life (approximately 2.5 hours), and platelet aggregation returns to near-normal levels within 4 hours of discontinuation. Eptifibatide can be removed by hemodialysis. Supportive measures should be employed, including monitoring of vital signs, coagulation parameters, and platelet counts. Platelet transfusions may be considered in cases of severe, uncontrolled bleeding.
What Are the Side Effects of Eptifibatide Ctruz?
The most common side effects of Eptifibatide Ctruz are related to its antiplatelet mechanism and include bleeding at various sites, from minor bruising to serious hemorrhage. Thrombocytopenia (low platelet count) can also occur. Most bleeding complications are manageable and resolve after stopping the infusion.
As with all medicines, eptifibatide can cause side effects, although not everybody gets them. The safety profile of eptifibatide has been established through large-scale clinical trials involving thousands of patients with acute coronary syndromes. Bleeding is the most clinically significant adverse effect, and its occurrence is influenced by the concomitant use of other antithrombotic agents, the presence of vascular access sites, and individual patient risk factors.
Very Common (affects more than 1 in 10 patients)
- Minor bleeding (oozing from puncture sites, gum bleeding, nosebleeds)
- Bleeding at the arterial access site (femoral artery puncture)
Common (affects 1 to 10 in 100 patients)
- Major bleeding (defined as hemoglobin drop ≥3 g/dl, need for transfusion, or intracranial hemorrhage)
- Hematoma at vascular access site
- Gastrointestinal bleeding
- Hematuria (blood in urine)
- Thrombocytopenia (platelet count <100,000/mm3)
Uncommon (affects 1 to 10 in 1,000 patients)
- Severe thrombocytopenia (platelet count <20,000/mm3)
- Intracranial hemorrhage
- Retroperitoneal bleeding
- Pulmonary hemorrhage
Rare (affects fewer than 1 in 1,000 patients)
- Fatal bleeding
- Acute profound thrombocytopenia (platelet count <10,000/mm3)
- Anaphylaxis or severe hypersensitivity reactions
In the landmark PURSUIT trial, which enrolled 10,948 patients, the incidence of major bleeding (non-CABG-related) was approximately 10.6% in the eptifibatide group compared with 9.1% in the placebo group. The incidence of intracranial hemorrhage was 0.08% in the eptifibatide group. Transfusion requirements were modestly higher in the eptifibatide group (11.8% vs 9.3%).
Thrombocytopenia is an important side effect that requires prompt recognition. In clinical trials, the incidence of thrombocytopenia (platelet count <100,000/mm3) was approximately 1.2% in the eptifibatide group compared with 0.6% in the placebo group. Severe thrombocytopenia (<20,000/mm3) occurred in approximately 0.2% of eptifibatide-treated patients. Thrombocytopenia typically develops within the first 24 hours of treatment and usually resolves within days of discontinuation.
Since eptifibatide is administered in a hospital setting, patients are continuously monitored. However, patients should immediately alert their nurse or doctor if they notice: unusual bleeding or bruising, blood in urine or stool, vomiting blood or material that looks like coffee grounds, severe headache, dizziness, or changes in vision, or any signs of an allergic reaction such as rash, itching, swelling, or difficulty breathing.
How Should You Store Eptifibatide Ctruz?
Eptifibatide Ctruz should be stored in a refrigerator (2°C to 8°C) and protected from light. The vial may be kept at room temperature (up to 25°C) for a single period not exceeding 2 months. Once the vial is opened, the solution should be used immediately.
Proper storage of eptifibatide is essential to maintain the stability and efficacy of the medication. As a hospital-administered product, storage is managed by pharmacy staff, but the following guidelines should be observed:
- Primary storage: Store in a refrigerator at 2°C to 8°C (36°F to 46°F)
- Protect from light: Keep the vial in the outer carton until ready for use
- Room temperature storage: The vial may be transferred to room temperature storage (up to 25°C / 77°F) for a single period not exceeding 2 months
- Do not freeze: Freezing may compromise the integrity of the peptide structure
- Do not use after expiry date: The expiry date refers to the last day of that month
- Visual inspection: Before use, inspect the solution for particulate matter and discoloration; the solution should be clear and colorless
- Single use: Discard any unused portion after opening; do not return to refrigerator for later use
Keep this medicine out of the sight and reach of children. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Does Eptifibatide Ctruz Contain?
Eptifibatide Ctruz contains the active substance eptifibatide at a concentration of 0.75 mg/ml in a sterile solution for intravenous infusion. The excipients include citric acid monohydrate, sodium hydroxide, and water for injections.
Each milliliter of Eptifibatide Ctruz solution for infusion contains 0.75 mg of eptifibatide as the active substance. Eptifibatide is a synthetic cyclic heptapeptide containing six amino acids and one mercaptopropionyl (desamino cysteinyl) residue. Its molecular formula is C35H49N9O9S, with a molecular weight of approximately 831.96 daltons.
The other ingredients (excipients) are:
- Citric acid monohydrate — used as a buffer to maintain the pH of the solution within the optimal range (approximately pH 5.35)
- Sodium hydroxide — used for pH adjustment
- Water for injections — serves as the solvent for the active ingredient and excipients
The solution is clear and colorless. It is supplied in glass vials of 100 ml containing 75 mg of eptifibatide. The product does not contain preservatives and is intended for single use only. Any unused solution should be discarded in accordance with local requirements for pharmaceutical waste disposal.
Eptifibatide Ctruz is compatible with 0.9% sodium chloride solution and 5% dextrose in water for intravenous administration. It may be administered through the same intravenous line as these solutions. The product should not be mixed with other medicinal products in the same infusion container or administered through the same intravenous line as furosemide (frusemide).
Frequently Asked Questions About Eptifibatide Ctruz
Medical References and Sources
All information in this article is based on internationally recognized medical guidelines and peer-reviewed scientific literature. The following sources form the evidence base for this content:
- The PURSUIT Trial Investigators. Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes. N Engl J Med. 1998;339(7):436-443. doi:10.1056/NEJM199808133390704
- The ESPRIT Investigators. Novel Dosing Regimen of Eptifibatide in Planned Coronary Stent Implantation (ESPRIT): A Randomised, Placebo-Controlled Trial. Lancet. 2000;356(9247):2037-2044. doi:10.1016/S0140-6736(00)03400-0
- European Society of Cardiology (ESC). 2023 ESC Guidelines for the Management of Acute Coronary Syndromes. Eur Heart J. 2023;44(38):3720-3826.
- Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2014;64(24):e139-e228.
- European Medicines Agency (EMA). Summary of Product Characteristics — Eptifibatide. Available at: www.ema.europa.eu
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List (2023). Geneva: WHO; 2023.
- Schneider DJ. Anti-platelet therapy: glycoprotein IIb-IIIa antagonists. Br J Clin Pharmacol. 2011;72(4):672-682. doi:10.1111/j.1365-2125.2010.03879.x
- De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005;293(14):1759-1765.
- British National Formulary (BNF). Eptifibatide. National Institute for Health and Care Excellence. Available at: bnf.nice.org.uk
- Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359(9302):189-198.
About Our Medical Editorial Team
This article has been written and reviewed by our medical editorial team, which includes specialist physicians in cardiology, hematology, and clinical pharmacology. All medical content follows our strict editorial standards and is based on the GRADE evidence framework.
📋 Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
🔍 Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
🔄 Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
✏️ Corrections Policy
Any errors are corrected immediately with transparent changelog. Read more
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in cardiology, hematology, clinical pharmacology, and emergency medicine.